Adaptimmune Therapeutics PLC
ADAPY· OTC
ADAPYAdaptimmune Therapeutics PLC
Quarterly figures for Adaptimmune Therapeutics PLC, with source filings when available.
41 quarters. Mar 31, 2015 to Jun 30, 2025. USD.
Adaptimmune Therapeutics PLC has filed its 10-Q within 39 to 45 days of period end across its last 8 quarters. The 10-K runs 56 to 83 days.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Source trail |
|---|---|---|---|---|---|---|---|---|---|
| FY 2025 | |||||||||
| Q2 2025 | Jun 30, 2025 | Aug 13, 2025 · pre-market | Aug 13, 2025 | 44 d | 10-Q | $13.68M | −89.3% | -$0.02 | |
| Q1 2025 |
|---|
| Mar 31, 2025 |
| May 13, 2025 · pre-market |
| May 13, 2025 |
| 43 d |
| 10-Q |
| $7.29M |
| +28.3% |
| -$0.03 |
| FY 2024 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2024derived | Dec 31, 2024 | Mar 20, 2025 · pre-market | Mar 24, 2025 | 83 d | 10-K | $3.22M | +1,294.8% | — | |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 · after-hours | Nov 13, 2024 | 44 d | 10-Q | $40.90M | +458.8% | -$0.01 | |
| Q2 2024 | Jun 30, 2024 | Aug 12, 2024 · pre-market | Aug 12, 2024 | 43 d | 10-Q | $128.23M | +2,399.6% | $0.04 | |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 · pre-market | May 15, 2024 | 45 d | 10-Q | $5.68M | −88.1% | -$0.03 | |
| FY 2023 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2023derived | Dec 31, 2023 | Mar 6, 2024 · pre-market | Mar 6, 2024 | 66 d | 10-K | $231.00K | −97.9% | — | |
| Q3 2023 | Sep 30, 2023 | Nov 8, 2023 · pre-market | Nov 8, 2023 | 39 d | 10-Q | $7.32M | +4.5% | -$0.03 | |
| Q2 2023 | Jun 30, 2023 | Aug 9, 2023 · pre-market | Aug 9, 2023 | 40 d | 10-Q | $5.13M | −7.4% | -$0.02 | |
| Q1 2023 | Mar 31, 2023 | May 12, 2023 · pre-market | May 12, 2023 | 42 d | 10-Q | $47.60M | +1,231.5% | $0.00 | |
| FY 2022 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2022derived | Dec 31, 2022 | Mar 6, 2023 · pre-market | Mar 6, 2023 | 65 d | 10-K | $11.03M | +678.3% | — | |
| Q3 2022 | Sep 30, 2022 | Nov 8, 2022 · pre-market | Nov 8, 2022 | 39 d | 10-Q | $7.01M | +482.5% | -$0.04 | |
| Q2 2022 | Jun 30, 2022 | Aug 4, 2022 · pre-market | Aug 4, 2022 | 35 d | 10-Q | $5.54M | +78.9% | -$0.05 | |
| Q1 2022 | Mar 31, 2022 | May 9, 2022 · pre-market | May 9, 2022 | 39 d | 10-Q | $3.58M | +723.7% | -$0.05 | |
| FY 2021 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2021derived | Dec 31, 2021 | Mar 14, 2022 · pre-market | Mar 14, 2022 | 73 d | 10-K | $1.42M | −5.7% | — | |
| Q3 2021 | Sep 30, 2021 | Nov 4, 2021 · pre-market | Nov 4, 2021 | 35 d | 10-Q | $1.20M | +0.8% | -$0.05 | |
| Q2 2021 | Jun 30, 2021 | Aug 9, 2021 · after-hours | Aug 9, 2021 | 40 d | 10-Q | $3.10M | +516.5% | -$0.04 | |
| Q1 2021 | Mar 31, 2021 | May 6, 2021 · pre-market | May 6, 2021 | 36 d | 10-Q | $434.00K | −43.0% | -$0.04 | |
| FY 2020 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2020derived | Dec 31, 2020 | Feb 25, 2021 · pre-market | Feb 25, 2021 | 56 d | 10-K | $1.50M | +106.3% | — | |
| Q3 2020 | Sep 30, 2020 | Nov 5, 2020 · pre-market | Nov 5, 2020 | 36 d | 10-Q | $1.19M | +403.4% | -$0.04 | |
| Q2 2020 | Jun 30, 2020 | Aug 6, 2020 · pre-market | Aug 6, 2020 | 37 d | 10-Q | $502.00K | +219.7% | -$0.04 | |
| Q1 2020 | Mar 31, 2020 | May 14, 2020 · pre-market | May 14, 2020 | 44 d | 10-Q | $761.00K | — | -$0.04 | |
| FY 2019 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2019derived | Dec 31, 2019 | Feb 27, 2020 · pre-market | Feb 27, 2020 | 58 d | 10-K | $728.00K | −50.8% | — | |
| Q3 2019 | Sep 30, 2019 | Nov 6, 2019 · pre-market | Nov 6, 2019 | 37 d | 10-Q | $237.00K | −99.4% | -$0.06 | |
| Q2 2019 | Jun 30, 2019 | Aug 1, 2019 · pre-market | Aug 1, 2019 | 32 d | 10-Q | $157.00K | −98.3% | -$0.07 | |
| Q1 2019 | Mar 31, 2019 | May 6, 2019 · pre-market | May 6, 2019 | 36 d | 10-Q | $0.00 | −100.0% | -$0.04 | |
| FY 2018 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2018derived | Dec 31, 2018 | Feb 27, 2019 · pre-market | Feb 27, 2019 | 58 d | 10-K | $1.48M | −65.4% | — | |
| Q3 2018 | Sep 30, 2018 | Nov 6, 2018 · pre-market | Nov 6, 2018 | 37 d | 10-Q | $40.79M | +50.1% | $0.01 | |
| Q2 2018 | Jun 30, 2018 | Aug 2, 2018 · pre-market | Aug 2, 2018 | 33 d | 10-Q | $9.04M | +156.7% | -$0.08 | |
| Q1 2018 | Mar 31, 2018 | May 9, 2018 · pre-market | May 9, 2018 | 39 d | 10-Q | $8.20M | +186.9% | -$0.04 | |
| FY 2017 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2017derived | Dec 31, 2017 | Mar 15, 2018 · pre-market | Mar 15, 2018 | 74 d | 10-K | $4.27M | −50.0% | — | |
| Q3 2017 | Sep 30, 2017 | Nov 2, 2017 · pre-market | Nov 2, 2017 | 33 d | 10-Q | $27.19M | +1,025.2% | $0.00 | |
| Q2 2017 | Jun 30, 2017 | Aug 3, 2017 · pre-market | Aug 3, 2017 | 34 d | 10-Q | $3.52M | +973.5% | -$0.04 | |
| Q1 2017 | Mar 31, 2017 | May 10, 2017 · pre-market | May 10, 2017 | 40 d | 10-Q | $2.86M | −2.1% | -$0.05 | |
| FY 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q4 2016derived | Dec 31, 2016 | Mar 13, 2017 · pre-market | Mar 13, 2017 | 72 d | 10-K | $8.54M | — | — | |
| Q3 2016 | Sep 30, 2016 | Nov 10, 2016 · pre-market | Nov 10, 2016 | 41 d | 10-Q | $2.42M | −51.2% | -$0.04 | |
| Q2 2016 | Jun 30, 2016 | Aug 8, 2016 · pre-market | Aug 8, 2016 | 39 d | 10-Q | $328.00K | −88.2% | -$0.05 | |
| Q1 2016 | Mar 31, 2016 | May 12, 2016 · pre-market | May 12, 2016 | 42 d | 10-Q | $2.92M | +7.0% | -$0.04 | |
| FY 2015 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Q3 2015 | Sep 30, 2015 | — | — | — | — | $4.95M | — | -$0.01 | |
| Q2 2015 | Jun 30, 2015 | — | — | — | — | $2.78M | — | -$0.05 | |
| Q1 2015 | Mar 31, 2015 | — | — | — | — | $2.73M | — | -$0.05 | |
